How MedWatch Reduced GLP-1 Costs by 70% While Improving Employee Outcomes

The Challenge: Can Employers Afford to Expand GLP-1 Access?

GLP-1 medications have quickly become one of the most discussed topics in healthcare.

Like many organizations, MedWatch saw increased demand for GLP-1 medications, rising obesity rates, and growing healthcare costs. Leadership recognized the potential health benefits these medications could offer employees but also shared a concern many employers are grappling with today:

How do you provide access to effective treatment without creating an unsustainable cost burden for the health plan?

The challenge was particularly important given the connection between obesity and chronic disease. According to the CDC, more than 40% of U.S. adults have obesity, and obesity-related medical expenditures total nearly $173 billion annually. Like many employers, MedWatch was seeing the downstream effects, including increased prevalence of obesity-related conditions such as Type 2 diabetes and the growing demand for GLP-1 therapies.

For some MedWatch employees managing Type 2 diabetes, costs associated with GLP-1 medications, physician visits, and related care averaged $15,600 annually.

Rather than simply recommending a solution to clients, MedWatch chose to evaluate a GLP-1 management strategy within its own employee population first.

A Different Approach

As a population health management company, MedWatch routinely evaluates health and wellness solutions for employers nationwide. Instead of relying solely on vendor claims or published outcomes, the organization elected to implement a GLP-1 program internally and evaluate the results firsthand.

After evaluating several options, MedWatch implemented a medically supervised weight management program that combines GLP-1 medication with clinical oversight, behavioral coaching, a lower-dose prescribing strategy, and long-term maintenance support.

The program was implemented over a 90-day period. Eligible employees enrolled in the program, met with clinicians and health coaches, received medication when appropriate, and participated in ongoing coaching designed to support lasting lifestyle changes.

One lesson emerged early:

Sustainable outcomes require more than medication alone.

As one participant explained:

“We’re doing the mental work to change behavior and evaluate my ongoing relationship with food and exercise to make this a lasting change.”

Results After 10 Months

The program delivered meaningful improvements in engagement, weight loss, employee satisfaction, and health plan performance. While participants initially enrolled for weight-loss support, many ultimately cited coaching, accountability, and behavior change support as key factors in long-term success.

Key Outcomes

High Member Satisfaction

Moving Employees into Lower-Risk Categories

Weight loss was only part of the story.

While pounds are easy to measure, employers are often more interested in whether health risks are actually changing. One of the most meaningful outcomes was the number of employees who moved out of the highest obesity classifications.

According to the Journal of Managed Care & Specialty Pharmacy, this matters because obesity severity is associated with increased risks of diabetes, cardiovascular disease, hypertension, and higher healthcare spending. Research has consistently shown that medical costs rise as obesity severity increases, making movement into lower-risk categories beneficial for both employees and employer-sponsored health plans.

For MedWatch, these changes represented more than lower healthcare costs. They reflected reduced health risks, improved quality of life, and better long-term health outcomes for participating employees.

Financial Impact

The results were not limited to employee health.

The program also produced meaningful financial outcomes for the health plan.

Additional financial outcomes included:

• 30% of participants reduced annual claims costs by more than $5,000
• Lower medication utilization
• Fewer reported side effects
• Projected break-even within the program’s first year

Most importantly, these savings were achieved while increasing access to treatment and improving employee outcomes.

For many employers, conversations about GLP-1 medications quickly became conversations about cost. MedWatch’s experience demonstrates that expanding access to effective treatment does not necessarily have to come at the expense of long-term plan sustainability.

The organization was able to improve employee outcomes while also reducing one of the fastest growing cost pressures facing employer-sponsored health plans.

What Employers Can Learn

Months after launch, MedWatch achieved:

• 85% participant retention
• 2,100+ pounds lost
• 97% satisfaction
• Significant movement out of high-risk obesity categories
• 70% lower GLP-1 costs
• Projected break-even within the first year

This experience reinforced a simple but important lesson:

Medication can be a powerful tool, but lasting results are driven by what happens between doses.

When GLP-1 therapy is combined with coaching, accountability, clinical oversight, and behavior change support, employers can create better outcomes for employees while improving the long-term sustainability of their health plans.

*Participation, satisfaction, and clinical outcomes data were collected through program reporting. Claims and financial analyses were based on MedWatch health plan data.